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Response to Correspondence by de Borst re: ‘The True Risk
of Early Recurrent Stroke: Importance of Cohort
Composition and Index Event Deﬁnition’
We read with interest the invited commentary of de Borst1
in response to our recent article on the risk of early
recurrent stroke in a population with symptomatic carotid
stenosis, and would like to take the opportunity to clarify a
few points.2
De Borst argues that we underestimate the actual risk
of recurrent stroke by deﬁning the index event as the
event that resulted in referral to hospital. We consider
that the alternative, to deﬁne the index event as the very
ﬁrst neurological event would risk overestimating the rate
of recurrence because the calculation/estimation/assess-
ment will not include all patients with an event without
neurological recurrence, who do not seek medical atten-
tion. Therefore, it is our view that a valid recurrence rate
can only be calculated from events occurring after a
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We would like to thank the authors of this letter for giving
us the opportunity to discuss some practical issues on the
use of NOAs in the management of VTE, which were not the
subject of our meta-analysis.1
We fully agree with the statement regarding the short
half-life and rapid onset of action of NOAs, which can be
discontinued and resumed rapidly pre- and post-operatively
for elective procedures, and that their use shortens the
window of risk for thromboembolism in patients treated for
either atrial ﬁbrillation or venous thromboembolism. These
are scenarios that are faced everyday in clinical practice; the
appropriate solution can be provided if the pharmacological
properties of the various NOAs are known.
We mentioned in the discussion section of our meta-
analysis the “different pharmacological properties, pharma-
codynamics, anticoagulation intensity, and dosing schedules of
the various agents.” These are recognized issues and the ﬁrst
two are the result of the different molecular structure of the
various NOAs. We would like to congratulate the authors formaking a table to compare these novel anticoagulants in terms
of mode of action and indication for use. We would like to
point out that for the treatment of venous thromboembolism
the recommended dose of rivaroxaban is 20 mg OD after the
ﬁrst 3 weeks of treatment. Similarly for apixaban, currently
approved to treat venous thromboembolism in the European
Union, the therapeutic dose is 5mgBD (10mgBD for theﬁrst 7
days). Continuous medical education is obviously extremely
important for all physicians and part of this is accomplished by
attending educational seminars and conferences run by pro-
fessional societies like I.S.E.T.A.T. (Institute For The Study And
Education On Thrombosis And Antithrombotic Therapy,
http://www.imetha.gr/EN/) in our country.
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